Diffuse large B-cell lymphoma recurrent
Information
- Disease name
- Diffuse large B-cell lymphoma recurrent
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01805557 | Completed | Phase 2/Phase 3 | Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. | February 4, 2013 | November 20, 2020 |
| NCT03589469 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | August 1, 2018 | August 9, 2022 |
| NCT05169203 | Completed | The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study | January 1, 2014 | January 1, 2021 | |
| NCT06086197 | Recruiting | Phase 2 | A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL | January 1, 2023 | October 2026 |
| NCT06033820 | Recruiting | Phase 2 | Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL | October 12, 2023 | June 30, 2025 |
| NCT03795571 | Unknown status | Phase 1 | Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL | January 1, 2019 | December 31, 2019 |
| NCT02955628 | Unknown status | Phase 2 | RICE-ibrutinib in Relapsed DLBCL | December 13, 2016 | August 2023 |
| NCT05966233 | Withdrawn | Phase 2 | R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma | January 2024 | January 2029 |